A major breakthrough in the treatment of heart failure with the Chinese medicine Qili Qiangxin

On August 2, 2024, the Chinese research team published a research result on the treatment of heart failure with reduced ejection fraction with the traditional Chinese medicine Qili Qiangxin in the international top medical journal Nature Medicine. Like a shining star, it illuminates a new journey in the field of heart failure treatment. This research result is not only an important milestone in the modernization of traditional Chinese medicine, but also brings new hope to countless heart failure patients around the world.

Heart failure, as the terminal stage of various cardiovascular diseases, has always been one of the major challenges facing the global medical field. Heart failure with reduced ejection fraction is characterized by the inability of the heart to effectively pump blood to various parts of the body, causing patients to experience symptoms such as dyspnea, fatigue, and edema, which seriously affects the quality of life and even endangers life. Although the current treatment methods can relieve symptoms and delay the progression of the disease to a certain extent, there are still many limitations, and the prognosis of many patients is still not optimistic.

The emergence of the traditional Chinese medicine Qili Qiangxin has brought a turning point to this dilemma. Qili Qiangxin is a traditional Chinese medicine compound preparation, whose ingredients include astragalus, ginseng, aconite, salvia miltiorrhiza, scutellaria baicalensis and other Chinese medicinal materials. In traditional Chinese medicine theory, these herbs have the effects of invigorating qi and warming yang, promoting blood circulation and unblocking collaterals, and promoting diuresis and reducing swelling. However, to apply them to the modern medical system and gain recognition from the international medical community, rigorous scientific research and clinical verification are needed.

This study by the Chinese research team is based on scientific methods and strict clinical trial design to conduct a comprehensive and in-depth evaluation of the efficacy and safety of Qili Qiangxin in the treatment of heart failure with reduced ejection fraction. The study included thousands of patients and adopted a randomized, double-blind, placebo-controlled research method to ensure the reliability and objectivity of the research results.

After a long period of follow-up observation and data analysis, the results are exciting. Qili Qiangxin combined with standardized treatment significantly reduced the risk of the main composite endpoint event (cardiovascular death and rehospitalization due to worsening heart failure) by 22%; significantly reduced the risk of rehospitalization due to worsening heart failure by 24% and the risk of cardiovascular death by 17%. This means that for patients with heart failure with reduced ejection fraction, adding Qili Qiangxin on the basis of conventional treatment can further improve prognosis, reduce the occurrence of adverse events, and bring more hope of survival and better quality of life to patients.

The significance of this research result is not only to provide a new effective drug for the treatment of heart failure, but also to provide strong evidence and examples for the modernization and international development of traditional Chinese medicine. For a long time, traditional Chinese medicine has been facing many doubts and challenges internationally, and the lack of scientific verification of its efficacy and safety is an important reason. The publication of this research result has allowed the world to see the scientificity and effectiveness of traditional Chinese medicine, and opened a new door for traditional Chinese medicine to go global.

At the same time, this study also reveals the unique concept and mechanism of traditional Chinese medicine in treating diseases. Traditional Chinese medicine emphasizes the overall concept and syndrome differentiation and treatment, and focuses on regulating the body's internal balance and immune system function. The mechanism of action of Qili Qiangxin may not only be a direct effect on the heart, but also include the regulation of qi and blood, yin and yang throughout the body, and comprehensive intervention in multiple links such as the neuroendocrine system and the immune system. This multi-target, multi-pathway treatment model provides new ideas and methods for modern medicine to treat complex diseases.

However, we must also be aware that this research result is just a beginning. Although Qili Qiangxin has shown significant efficacy in clinical trials, in actual applications, it is necessary to further explore its optimal dosage, timing of use, and combined application with other drugs. In addition, in-depth research on its mechanism of action also requires more scientific research efforts to better reveal the secrets of traditional Chinese medicine and provide theoretical support for its wider application.

In future medical practice, we look forward to the wider application and promotion of Qili Qiangxin, which will bring good news to more patients with heart failure. At the same time, we also hope that this research result can inspire more scientific researchers to devote themselves to the modernization of traditional Chinese medicine, promote the development and dissemination of traditional Chinese medicine on a global scale, and make greater contributions to human health.

In short, the research results published by the Chinese research team in Nature Medicine on the treatment of heart failure with reduced ejection fraction with Qili Qiangxin are a major achievement in my country's medical research field and an important step for traditional Chinese medicine to go global. I believe that in the near future, traditional Chinese medicine will play a more important role in the global medical field and bring more benefits to human health.